title: Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles.
abstract: Self-amplifying RNA or RNA replicon is a form of nucleic acid-based vaccine derived from either positive-strand or negative-strand RNA viruses. The gene sequences encoding structural proteins in these RNA viruses are replaced by mRNA encoding antigens of interest as well as by RNA polymerase for replication and transcription. This kind of vaccine has been successfully assayed with many different antigens as vaccines candidates, and has been shown to be potent in several animal species, including mice, nonhuman primates, and humans. A key challenge to realizing the broad potential of self-amplifying vaccines is the need for safe and effective delivery methods. Ideally, an RNA nanocarrier should provide protection from blood nucleases and extended blood circulation, which ultimately would increase the possibility of reaching the target tissue. The delivery system must then be internalized by the target cell and, upon receptor-mediated endocytosis, must be able to escape from the endosomal compartment into the cell cytoplasm, where the RNA machinery is located, while avoiding degradation by lysosomal enzymes. Further, delivery systems for systemic administration ought to be well tolerated upon administration. They should be safe, enabling the multiadministration treatment modalities required for improved clinical outcomes and, from a developmental point of view, production of large batches with reproducible specifications is also desirable. In this review, the concept of self-amplifying RNA vaccines and the most promising lipid-based delivery systems are discussed.
authors.affiliation: Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Rodríguez-Gascón
authors.affiliation: Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
authors.forename: Ana
authors.initials: A
authors.lastname: del Pozo-Rodríguez
authors.affiliation: Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Centro de Investigación Lascaray Ikergunea, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
authors.forename: María Ángeles
authors.initials: MÁ
authors.lastname: Solinís
mesh_terms: D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000008:administration & dosage / Q000138:chemical synthesis*; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry* / Q000648:ultrastructure*; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D012313:RNA; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000138:chemical synthesis*
chemical_list: D008055:Lipids; D008081:Liposomes; D053769:Nanocapsules; D019444:Vaccines, DNA; D012313:RNA
keywords: RNA replicon; liposomes; nucleic acid vaccines; self-amplifying RNA vaccine; solid lipid nanoparticles
references.citation: Methods Mol Biol. 2013;969:235-46
references.pmid: 23296938
references.citation: Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-80
references.pmid: 20402623
references.citation: PLoS One. 2012;7(1):e29732
references.pmid: 22238645
references.citation: Emerg Microbes Infect. 2013 Aug;2(8):e52
references.pmid: 26038486
references.citation: J Virol. 2010 Apr;84(8):3798-807
references.pmid: 20130066
references.citation: Drug Des Devel Ther. 2012;6:303-10
references.pmid: 23118528
references.citation: J Control Release. 2010 May 10;143(3):311-7
references.pmid: 20080139
references.citation: Biochim Biophys Acta. 1996 Jun 11;1281(2):139-49
references.pmid: 8664312
references.citation: Adv Virus Res. 2008;72:77-126
references.pmid: 19081489
references.citation: J Virol. 2013 Feb;87(3):1290-300
references.pmid: 23175362
references.citation: Expert Rev Vaccines. 2012 Jan;11(1):55-67
references.pmid: 22149709
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1951-6
references.pmid: 14769933
references.citation: Int J Pharm. 2011 Sep 20;416(2):402-9
references.pmid: 21291974
references.citation: Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9
references.pmid: 22908294
references.citation: J Control Release. 2008 May 22;128(1):89-97
references.pmid: 18384902
references.citation: Vaccine. 2012 Jan 17;30(4):758-66
references.pmid: 22133510
references.citation: J Immunother. 2008 Feb-Mar;31(2):180-8
references.pmid: 18481387
references.citation: J Biol Chem. 1995 Aug 11;270(32):18997-9007
references.pmid: 7642560
references.citation: Colloids Surf B Biointerfaces. 2010 Sep 1;79(2):509-15
references.pmid: 20541375
references.citation: Eur J Pharm Biopharm. 2009 Feb;71(2):181-9
references.pmid: 18940256
references.citation: Semin Immunol. 2013 Apr;25(2):152-9
references.pmid: 23735226
references.citation: Nature. 2008 Apr 3;452(7187):591-7
references.pmid: 18368052
references.citation: J Gene Med. 2007 Oct;9(10):833-42
references.pmid: 17721874
references.citation: Vaccine. 2007 Feb 26;25(10):1701-11
references.pmid: 17240490
references.citation: J Virol. 2012 Mar;86(6):2900-10
references.pmid: 22258243
references.citation: Biomaterials. 2004 Jul;25(16):3267-73
references.pmid: 14980421
references.citation: Colloids Surf B Biointerfaces. 2013 Dec 1;112:530-6
references.pmid: 24079942
references.citation: Arch Pharm Res. 2009 May;32(5):639-46
references.pmid: 19471876
references.citation: J Biomed Biotechnol. 2010;2010:690438
references.pmid: 20671921
references.citation: Curr Opin Allergy Clin Immunol. 2010 Dec;10(6):567-74
references.pmid: 20856111
references.citation: Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):12881-6
references.pmid: 23882076
references.citation: Mol Pharm. 2013 Sep 3;10(9):3366-74
references.pmid: 23924216
references.citation: Cancer Immunol Immunother. 2013 Feb;62(2):285-97
references.pmid: 22903385
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):161-77
references.pmid: 10840199
references.citation: Bioconjug Chem. 2007 Mar-Apr;18(2):302-8
references.pmid: 17253655
references.citation: Biotechniques. 2007 Nov;43(5):675-81
references.pmid: 18072597
references.citation: J Control Release. 2004 Sep 14;99(1):177-90
references.pmid: 15342190
references.citation: Pharm Res. 2004 Sep;21(9):1662-9
references.pmid: 15497694
references.citation: J Control Release. 2012 Jun 10;160(2):200-10
references.pmid: 22155599
references.citation: Acc Chem Res. 2012 Jul 17;45(7):1163-71
references.pmid: 22568781
references.citation: Viruses. 2010 Feb;2(2):413-434
references.pmid: 21994644
references.citation: Int J Pharm. 2012 Apr 4;425(1-2):35-43
references.pmid: 22226874
references.citation: J Drug Target. 2010 Jun;18(5):333-42
references.pmid: 19958051
references.citation: Expert Opin Drug Deliv. 2005 Mar;2(2):237-54
references.pmid: 16296751
references.citation: Science. 1990 Mar 23;247(4949 Pt 1):1465-8
references.pmid: 1690918
references.citation: Adv Genet. 2005;53PA:189-214
references.pmid: 16243064
references.citation: Mol Ther Nucleic Acids. 2013 Jun 04;2:e96
references.pmid: 23736774
references.citation: Nanomedicine. 2013 Feb;9(2):233-46
references.pmid: 22698807
references.citation: Vaccine. 2005 Jul 21;23(33):4189-94
references.pmid: 16005737
references.citation: Vaccine. 2009 Dec 11;28(2):484-93
references.pmid: 19857446
references.citation: Mol Ther. 2010 Feb;18(2):370-6
references.pmid: 19997090
references.citation: Curr Opin Immunol. 2011 Jun;23(3):399-406
references.pmid: 21497074
references.citation: Biomaterials. 2004 Dec;25(27):5893-903
references.pmid: 15172502
references.citation: Biomaterials. 2010 Apr;31(11):3079-86
references.pmid: 20092889
references.citation: Eur J Pharm Sci. 2013 Nov 20;50(3-4):484-91
references.pmid: 23981333
references.citation: Gene Ther. 2011 Jul;18(7):702-8
references.pmid: 21368901
references.citation: Science. 1993 Mar 19;259(5102):1745-9
references.pmid: 8456302
references.citation: Vaccine. 2009 Feb 18;27(8):1174-83
references.pmid: 19135116
references.citation: J Clin Oncol. 1997 Jan;15(1):341-9
references.pmid: 8996161
references.citation: Cancer Gene Ther. 2007 Sep;14(9):802-14
references.pmid: 17589432
references.citation: J Intern Med. 2003 Apr;253(4):402-10
references.pmid: 12653868
references.citation: J Virol. 2010 Aug;84(15):7713-25
references.pmid: 20504925
references.citation: Vaccine. 2012 Jun 22;30(30):4414-8
references.pmid: 22546329
references.citation: Nucleic Acids Res. 2001 Sep 15;29(18):3882-91
references.pmid: 11557821
references.citation: J Nanosci Nanotechnol. 2008 May;8(5):2187-204
references.pmid: 18572631
references.citation: Drug Discov Today. 2008 Jun;13(11-12):513-21
references.pmid: 18549978
references.citation: Eur J Pharm Biopharm. 2011 Nov;79(3):495-502
references.pmid: 21726641
references.citation: Eur J Immunol. 1993 Jul;23(7):1719-22
references.pmid: 8325342
references.citation: Nat Mater. 2013 Nov;12(11):967-77
references.pmid: 24150415
references.citation: J Control Release. 2009 Jan 5;133(1):52-9
references.pmid: 18854203
references.citation: Cancer Immunol Immunother. 2006 Mar;55(3):246-53
references.pmid: 16133114
references.citation: Immunol Rev. 2011 Jan;239(1):62-84
references.pmid: 21198665
references.citation: Int J Pharm. 2007 Aug 1;340(1-2):198-206
references.pmid: 17482778
references.citation: Handb Exp Pharmacol. 2008;(183):221-35
references.pmid: 18071662
references.citation: Eur J Pharm Biopharm. 2013 Jun;84(2):309-14
references.pmid: 23461861
references.citation: J Immunother. 2009 Jun;32(5):498-507
references.pmid: 19609242
references.citation: Clin Cancer Res. 2001 Aug;7(8):2285-91
references.pmid: 11489803
references.citation: Recent Pat Drug Deliv Formul. 2011 Sep;5(3):214-26
references.pmid: 21834776
references.citation: Vaccine. 2011 Jan 29;29(5):931-40
references.pmid: 21111777
references.citation: Int J Pharm. 2007 Jul 18;339(1-2):261-8
references.pmid: 17467205
references.citation: J Gen Virol. 2005 Apr;86(Pt 4):1045-1053
references.pmid: 15784898
references.citation: Pharmazie. 2011 Jul;66(7):473-8
references.pmid: 21812320
references.citation: Mol Ther. 2013 Jan;21(1):251-9
references.pmid: 23011030
references.citation: Mol Med Rep. 2009 Sep-Oct;2(5):753-6
references.pmid: 21475897
references.citation: Silence. 2010 Jul 08;1(1):14
references.pmid: 20615220
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077